Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
W A Macdonald
ResearcherPublications, citations & collaboration network
W A Macdonald is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 135 works, 2,935 citations, an h-index of 23 and an i10-index of 43.
135
Works
2,935
Citations
23
h-index
43
i10-index
IDs:OpenAlex
How has W A Macdonald's publication output changed over time?
ScholarIQpublication output · 1990–2025
Output grew0% over the shown period — from 1 works in 1990 to 1 in 2025.
1
1
1
1
1
1
1
3
1
199020012007200920132021202320242025
What are the most-cited papers on W A Macdonald?
ScholarIQmost cited works
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew Redfern, W A Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Y. Zhang, Margaret McJannett, Martin R. Stockler, John Violet, Scott Williams, Andrew Martin, Ian D. Davis, Arun Azad, Wei Chua, Ian D. Davis, Nattakorn Dhiantravan, Louise Emmett, Kate Ford, Michael S. Hofman, Roslyn J. Francis, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Edward Hsiao, Amir Iravani, Anthony M. Joshua, Ian Kirkwood, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Peter Lin, Andrew Martin, William M. McDonald, Margaret McJannett, Siobhan Ng, David A. Pattison, Shakher Ramdave, Nisha Rana, Andrew Redfern, Natalie Rutherford, Shahneen Sandhu, Andrew M. Scott, Martin R. Stockler, Shalini Subramaniam, Thean Hsiang Tan, John Violet, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang
The Lancet. 20211,112 Citations
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, James P Buteau, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew Redfern, W A Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Yan Zhang, Martin R. Stockler, Scott Williams, Andrew Martin, Ian D. Davis, Tim Akhurst, Ramin Alipour, Dale L. Bailey, Patricia Banks, Alexis Beaulieu, Louise Campbell, Megan Crumbaker, Nattakorn Dhiantravan, Anis Hamid, Mohammad B. Haskali, Terry Hung, Grace Kong, Nick Lawrence, Jeremy Lewin, Michael McCarthy, Kate Moodie, Declan G. Murphy, Andrew Nguyen, David Pook, Aravind Ravi Kumar, Paul Roach, Peter Roselt, Javad Saghebi, Geoffrey Schembri, Lavinia Spain, Shalini Subramaniam, Sue Ping Thang, Paul Thomas, Ben Tran, Roslyn E. Wallace, Sonia Yip
The Lancet Oncology. 2023210 Citations
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M. Joshua, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Craig Gedye, Natalie Rutherford, Shahneen Sandhu, Aravind Ravi Kumar, David Pook, Shakher Ramdave, David Nadebaum, Mark Voskoboynik, Andrew Redfern, W A Macdonald, Laurence E. Krieger, Geoffrey Schembri, Wei Chua, Peter Lin, Lisa G. Horvath, Patricia Bastick, Patrick Butler, Alison Yan Zhang, Sonia Yip, Hayley Thomas, Ailsa Langford, Michael S. Hofman, Margaret McJannett, Andrew Martin, Martin R. Stockler, Ian D. Davis
The Lancet Oncology. 2024170 Citations
Experimental manipulation of the dawn and dusk chorus in the blackbird Turdus merula
InnesC. Cuthill, W A Macdonald
S136529485. 1990142 Citations
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
Arun Azad, Mathias Bressel, Hsiang Tan, Mark Voskoboynik, Aneta Suder, Andrew Weickhardt, Alexander Guminski, Roslyn J. Francis, Javad Saghebi, Nattakorn Dhiantravan, Anthony M. Joshua, Louise Emmett, Lisa G. Horvath, Declan G. Murphy, Edward Hsiao, Bavanthi Balakrishnar, Peter Lin, Andrew Redfern, W A Macdonald, Siobhan Ng, Sze-Ting Lee, David A. Pattison, David Nadebaum, Ian Kirkwood, Michael S. Hofman, T Akhurst, R Alipour, L Au, P Banks, B Emerson, N Hussain, M Haskali, J Lewin, R Linklater, L Kostos, R Kashyap, P Krishanth, G Kong, A Kumar, D Murphy, P Roselt, S Sandhu, M Scalzo, B Tran, R Wallace, L Spain, H Bourke, A Milton, D Russo, M Bills, C Chew, W Hsieh, B Crouch, D Smyth, S Pandelus, H Lam, C Gan, J Goh, A Scott, U Hafeez, U Ackermann, K Young, A Poon, K Pathmaraj, G Schembri, P Roach, D Bailey, T Hung, A Asad, T Hagan, J Watts, E Campbell, W Chua, A Pal, M Crumbaker, A Nguyen, A Yam, J Chen, L Ardolino, K Kongrak, L Ratnayake
The Lancet Oncology. 2024124 Citations
Related on ScholarIQ
Fiona Stanley Hospital
Institution
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Paper
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Paper
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Paper
Experimental manipulation of the dawn and dusk chorus in the blackbird Turdus merula
Paper
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
Paper